SLG
ALXN

Stanley-Laman Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Stanley-Laman Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,562
Closed -$870K – 364
2015
Q4 		$870K Buy
+4,562
New +$797K 0.15% 159

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Stanley-Laman Group's ALXN Position: Q1 2016 in Review

Stanley-Laman Group sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 4,562 shares — an estimated $870K sold.

Stanley-Laman Group first reported a position in ALXN in Q4 2015 and held it in 1 quarter. The position peaked at $870K in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Stanley-Laman Group reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 4,562 Alexion Pharmaceuticals shares in Q1 2016, an estimated $870K.
  • Stanley-Laman Group first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Stanley-Laman Group's Alexion Pharmaceuticals position peaked at $870K in Q4 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Stanley-Laman Group's 13F filing for Q1 2016, filed 9 May 2016.